Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan, February 27, 2009 – Astellas US Holding, Inc., a wholly owned subsidiary of Astellas Pharma Inc., today announced that it has filed a lawsuit in the Delaware Chancery Court against...
Read more about ASTELLAS FILES LAWSUIT AGAINST CV THERAPEUTICS
Tokyo, Japan, February 27, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all...
Tokyo, Japan, February 23, 2009 – Astellas Pharma Inc. (“Astellas”) today commented on CV Therapeutics, Inc’s. (Nasdaq: CVTX) announcement that its Board of Directors has rejected...
Japan, February 3, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; president and CEO: Masafumi Nogimori) announced today that it will implement changes to its global development...
Read more about Astellas Announces Global Development Organizational Changes
Tokyo, Japan, January 27, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that it has submitted a proposal to the Board of Directors of CV Therapeutics, Inc. (Nasdaq: CVTX) to...
Read more about ASTELLAS PROPOSES TO ACQUIRE CV THERAPEUTICS FOR $16 PER SHARE IN CASH
Follow us
